Major trial launches for aggressive stomach cancers
Disease control
Not yet recruiting
This study is testing whether adding an experimental drug called TST001 to standard chemotherapy and immunotherapy helps people with advanced stomach or gastroesophageal cancer live longer without their cancer getting worse. The trial will involve 820 adults with a specific tumor…
Phase: PHASE3 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 23:26 UTC